Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ancient herbal mix put to the test against COVID-19

NCT ID NCT04939415

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a 21-herb formula called modified Qing Fei Pai Du Tang (mQFPD) in 60 adults with mild-to-moderate COVID-19. Participants took either the herb capsules or a placebo for 14 days. The main goal was to see if the formula is safe and feasible to use, not yet to prove it works. Researchers also looked at changes in viral load and symptoms as secondary measures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified Qing Fei Pai Du Tang (mQFPD), a 21-herb formula
What this could lead to
If it works, this could point toward a safe herbal treatment to ease mild-to-moderate COVID-19 symptoms.
What could go wrong
This is a very early phase 1 trial with only 60 people, so it is mainly checking safety, not whether it works. The results may not apply to everyone, and the herb mix could cause side effects or interact with other medicines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

60 people

The number who actually took part.

Started

Jul 2021

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Positive COVID-19 diagnosis within the prior 72 hours or within 9 days of symptom onset * Age 18 years and older * Women of childbearing potential must have a negative urine or serum hCG. * Women of childbearing potential must have a negative serum pregnancy test at screening and agree to use contraception throughout the study period. * Capable of documenting vitals, symptoms, and study product intake daily and communicating this information to the study team * Willing to try to minimize alcohol, cannabis, and dairy products during the study period. Exclusion Criteria: 1. Any of the following symptoms which, according to the CDC, require hospitalization: 1. Trouble breathing 2. Persistent pain or pressure in the chest 3. New confusion or inability to arouse 4. Bluish lips or face 2. Current use of investigational agents to prevent or treat COVID-19 3. Known liver disease (ALT/AST \>3x ULN or diagnosis of cirrhosis) 4. Known renal disease (eGFR \< 60 ml/min) or acute nephritis. 5. Uncontrolled hypertension (SBP\>140 or DBP\>90 while on medications) 6. Allergy to tree nuts 7. Bleeding dyscrasia or on anticoagulation (aspirin and/or clopidogrel is allowed) 8. Pregnant or breastfeeding women 9. Use of Tolbutamide 10. Use of systemic corticosteroids (hydrocortisone, cortisone, prednisolone, betamethasone, methylprednisolone, prednisone, dexamethasone). Inhaled budesonide is to be allowed. 11. Use of digoxin 12. Use of Oxacillin 13. Use of Interferon 14. Use of Vincristine 15. Use of Cyclosporine 16. Use of Amiodarone 17. Patients with a past medical history of epilepsy 18. Use of monoamine oxidase inhibitors (MAOI) 19. Use of Methamphetamine within the prior 30 days 20. Use of Cocaine within the prior 30 days 21. Use of aminoglycosides, carbamazepine, flecainide, lithium, phenytoin, phenobarbital, rifampicin, theophylline and warfarin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, San Diego

    San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.